section name header

Pronunciation

oh-loh-DAT-er-ole

Classifications

Therapeutic Classification: bronchodilators

Pharmacologic Classification: beta-adrenergic agonists

Indications

REMS


Action

  • A long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, resulting in accumulation of cyclic adenosine monophosphate (cAMP) at beta2-adrenergic receptors resulting in bronchodilation.
Therapeutic effects:
  • Bronchodilation with decreased airflow obstruction.

Pharmacokinetics

Absorption: 30% absorbed following oral inhalation (from lung surface); swallowed drug is minimally absorbed.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Extensively metabolized by the liver, some by the CYP3A4 isoenzyme; only one metabolite binds to beta2 adrenergic receptors. 5–7% excreted unchanged in urine, remainder in feces as drug and metabolites (84%).

Half-Life: 45 hr.

Time/Action Profile

(improvement in FEV1)
ROUTEONSETPEAKDURATION
Inhalnwithin 1 hr1–5 hr24 hr



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: BP, ECG changes, tachycardia

EENT: nasopharyngitis

Endo: hyperglycemia

F and E: hypokalemia

GI: diarrhea

MS: arthralgia, back pain

Neuro: dizziness.

Resp: cough, PARADOXICAL BRONCHOSPASM

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA)

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Striverdi Respimat